Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Davunetide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.46 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | NTSR2 | O95665 | 8/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 8/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 6/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Davunetide SCHEMBL239736 | 1.00 | XIAP (0.48) | XIAPAGTR2AGTR1CALCRLF2 | |
| Davunetide SCHEMBL3689039 | 1.00 | XIAP (0.48) | XIAPAGTR2AGTR1CALCRLF2 | |
| Davunetide SCHEMBL19712227 | 1.00 | XIAP (0.48) | XIAPAGTR2AGTR1CALCRLF2 | |
| SCHEMBL13035034 | 0.96 | XIAP (0.47) | XIAPAGTR2AGTR1CALCRLF2 | |
| SCHEMBL30056720 | 0.92 | CALCRL (0.42) | XIAPAGTR2AGTR1CALCRLF2 | |
| Hydrochloric Acid SCHEMBL30504557 | 0.92 | CALCRL (0.42) | XIAPAGTR2AGTR1CALCRLF2 | |
| SCHEMBL30777830 | 0.91 | XIAP (0.48) | XIAPAGTR2AGTR1CALCRLNTSR2 | |
| SCHEMBL14693963 | 0.91 | XIAP (0.53) | XIAPAGTR2AGTR1NTSR2NTSR1 | |
| SCHEMBL14693960 | 0.91 | XIAP (0.53) | XIAPAGTR2AGTR1NTSR2NTSR1 | |
| SCHEMBL29947945 | 0.87 | XIAP (0.53) | XIAPAGTR2AGTR1F2NTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2026-01-29 | — | — | US | claimed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| WO-2025226878-A2 | COMPOSITIONS AND METHODS FOR DELIVERING DNA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-10-30 | — | — | WO | claimed |
| US-20250312408-A1 | NAP FOR SEX-SPECIFIC TREATMENT OF DISEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-10-09 | — | — | US | claimed |
| US-12409162-B2 | Carbazole derivatives sensitizing cells to anti-cancer agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2025-09-09 | — | — | US | claimed |
| US-20250235641-A1 | DEVICE TO DELIVER A PREDETERMINED AMOUNT OF A SUBSTANCE TO A NATURAL ORIFICE OF THE BODY | APTARGROUP INC. (US) | 2025-07-24 | — | — | US | claimed |
| US-12227500-B2 | Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum stress | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-02-18 | — | — | US | claimed |
| CN-119452086-A | GAPMER antisense oligonucleotides with modified backbone chemistry | 奎里斯公司 | 2025-02-14 | — | — | CN | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20220409830-A1 | DEVICE TO DELIVER A PREDETERMINED AMOUNT OF A SUBSTANCE TO A NATURAL ORIFICE OF THE BODY | SIPNOSE LTD. (IL) | 2022-12-29 | — | — | US | claimed |
| WO-2022251306-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-01 | — | — | WO | claimed |
| US-20220380383-A1 | NEUROPROTECTIVE PDI MODULATING SMALL MOLECULES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-12-01 | — | — | US | claimed |
| US-20220372489-A1 | PPM1A INHIBITORS AND METHODS OF USING SAME | QURALIS CORPORATION | 2022-11-24 | — | — | US | claimed |
| WO-2022218876-A1 | PANCREATIC ISLET ORGANOIDS AS PROTEIN FACTORIES | BIOCRINE AB (SE) | 2022-10-20 | — | — | WO | claimed |
| US-20220305006-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-09-29 | — | — | US | claimed |
| EP-4041395-A1 | NEW CARBAZOLE DERIVATIVES SENSITIZING CELLS TO ANTI-CANCER AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-08-17 | — | — | EP | claimed |
| US-11383048-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | SIPNOSE LTD. (IL) | 2022-07-12 | — | — | US | claimed |
| EP-3987030-A2 | PPM1A INHIBITORS AND METHODS OF USING SAME | Quralis Corporation (US) | 2022-04-27 | — | — | EP | claimed |
| EP-3969444-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS | The Regents of the University of California (US) | 2022-03-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12409162-B2 | Carbazole derivatives sensitizing cells to anti-cancer agents | HDAC3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1 | XIAP 2633/4885AGTR2 2280/4885AGTR1 1522/4885 |
| US-12227500-B2 | Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum stress | HSPA5, ATP2A1, DNAJC10 | XIAP 685/4885AGTR2 3435/4885AGTR1 3595/4885 |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | TNF, PYCARD, VAPA | XIAP 640/4885AGTR2 661/4885AGTR1 1002/4885 |
| US-20220305006-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS | PSEN2, BACE1, PSEN1 | XIAP 615/4885AGTR2 1269/4885AGTR1 1556/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | XIAP 3858/4885AGTR2 95/4885AGTR1 60/4885 |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | HSPA5, ATP2A1, DNAJC10 | XIAP 685/4885AGTR2 3435/4885AGTR1 3595/4885 |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | ADM2, TAS2R42, ACP1 | XIAP 3252/4885AGTR2 1407/4885AGTR1 1191/4885 |
| US-20220380383-A1 | NEUROPROTECTIVE PDI MODULATING SMALL MOLECULES AND METHODS OF USE THEREOF | NLN, PDIA5, PRNP | XIAP 148/4885AGTR2 4079/4885AGTR1 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.